For whom is triple antihypertensive therapy indicated? Optimizing the management of arterial hypertension – patient profiles Review article
Article Sidebar
Main Article Content
Abstract
Hypertension is one of the most prevalent chronic, non-communicable diseases in the 21st century and represents a significant modifiable risk factor for cardiovascular diseases, including myocardial infarction, stroke, and heart failure. According to estimates from the World Health Organization, hypertension affects over one-third of the adult population globally, with prevalence rates reaching as high as 40–50% among individuals over the age of 60 in developed countries. The 2024 guidelines from the Polish Society of Hypertension (PTNT) and the Polish Cardiac Society (PTK) underlined several recommendations, one of the most significant changes being the shift towards the prompt initiation of triple therapy in patients at high and very high cardiovascular risk, as well as in those for whom dual therapy fails to achieve the desired therapeutic outcomes. Combination therapy involving perindopril, amlodipine, and indapamide is one of the most well-documented and practically utilized treatment regimens for hypertension in Europe. This study aims to comprehensively discuss this treatment scheme from clinical, pharmacological, and organizational perspectives, considering its position within the current PTNT/PTK 2024 guidelines and its importance for improving hypertension control among patients, including the Polish population.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. McEvoy JW, McCarthy CP, Bruno RM et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024; 45(38): 3912-4018.
3. Analiza danych NFZ 2022.
4. Analiza danych NFZ 2021.
5. Ocena w ramach kampanii May Measurement Month 2021.
6. Ocena w ramach badania POLSENIOR2 (2018–2019).
7. Badanie WOBASZ2 (2013–2014).
8. ESC. ESC CVD Risk Calculation App Individual cardiovascular risk assessment for healthcare professionals.
9. Roush GC, Ernst ME, Kostis JB et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015; 65(5): 1041-6.
10. Chen P, Chaugai S, Zhao F et al. Cardioprotective Effect of Thiazide-Like Diuretics: A Meta-Analysis. Am J Hypertens. 2015; 28(12): 1453-63.
11. Prejbisz A, Dobrowolski P, Doroszko A et al. Practical use of single pill combinations in the treatment of hypertension – an analysis focused on perindopril-based combinations. Arterial Hypertens. 2023; 27(3): 113-32.
12. Savarese G, Costanzo P, Cleland JG et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013; 61(2): 131-42.
13. Dahlöf B, Sever PS, Poulter NR et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Tria-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366(9489): 895-906.
14. Gupta A, Mackay J, Whitehouse A et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018; 392(10153): 1127-37.
15. Sever PS, Dahlöf B, Poulter NR et al. For the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361: 1149-58.
16. Zoungas S, Chalmers J, Neal B et al.; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014; 371(15): 1392-406.
17. Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590): 829-40.
18. Chalmers J, Mourad JJ, Brzozowska-Villatte R et al. Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials. J Hypertens. 2023; 41(3): 508-15.
19. Tóth K; PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014; 14(2): 137-45.
20. Chalmers J, Arima H, Woodward M et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014; 63(2): 259-64.
21. Snyman JR, Bortolotto LA, Degli Esposti L et al. A real-world analysis of outcomes and healthcare costs of patients on perindopril/indapamide/ amlodipine single-pill vs. multiple-pill combination in Italy. J Hypertens. 2024; 42(1): 136-42.
22. Agarwal R, Sinha AD, Cramer AE et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021; 385: 2507-19.
23. Beckett NS, Peters R, Fletcher AE et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358(18): 1887-98.